ClinicalTrials.gg
CompletedNCT03138018AGINGUpdated Oct 26, 2026

Aging Stereotypes and Prodromal Alzheimer's Disease

An interventional study of Diagnosis of MCI versus No MCI (SCI or healthy patient) and Diagnosis of MCI versus No MCI (SCI or healthy patient) in Mild Cognitive Impairment (MCI), sponsored by Assistance Publique Hopitaux De Marseille. Completed at 1 site in France. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 26, 2026Now CompletedResults publication added+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 189 studies in Cognitive Dysfunction with a site in France — 52 open to participants now, 60 under way, 6 of them phase 3. Cognitive Dysfunction · France.

Enrollment
57th of 139
130 · median 88
Started
2018
with 4 others
No phase
104 of 189
32 open now
Registered
71st of 189
by date

Among the 189 studies in Cognitive Dysfunction with a site in France, this one is the 57th largest by enrollment of the 139 interventional ones that give a count, is one of 5 that started in 2018, is one of 104 with no phase, and was the 71st registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

52 of the 189 studies in Cognitive Dysfunction with a site in France are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Cognitive Dysfunction with a site in France, or all of them as a file.
02

Study summary

Because of the lengthening of life expectancy, more and more people are concerned with the effects of aging on their mental faculties (e.g., memory decline) and with the possibility of getting Alzheimer's Disease (AD) or other forms of dementia. This increasing awareness of AD has already resulted in a growing demand for neuropsychological testing. AD's research also emphasizes the need for early screening to improve the prediction of the disease progression and the efficacy of any future therapy. Such a drive to screen for pre-dementia raises the challenging issue of frontline identification of individuals in the preclinical or early clinical stages of AD. Mild Cognitive Impairment (MCI) is typically considered to be the prodromal state of AD, and is therefore at the core of the drive for early screening. Moreover, Pre-MCI so called SCI (Subjective Cognitive Impairment) can precede AD for 15 years. However, many individuals diagnosed with MCI do not convert to AD, some remaining stable and others even reversing back to normal (with rates of reversion to normal varying from 4.5% to as high as 53%). This over-diagnosis bias, which has been largely overlooked, is at the core of the present project at the interface of human and life sciences. Here, we argue that an important source of overdiagnosis in the prodromal state of AD comes from negative aging stereotypes (e.g., the culturally shared beliefs that aging inescapably causes severe cognitive decline and diseases such as AD) that permeate neuropsychological screening. There is ample evidence in the laboratory that such stereotypes contribute to the differences observed in the healthy population between younger and older adults in explicit memory tasks. Additionally, three pilot (lab) studies specifically conducted for the present ANR project showed that the threat of being judged stereotypically undermines the controlled use of memory of healthy older adults and simultaneously intensifies their automatic response tendencies, resulting in impaired memory performance. The present proposal goes several steps further by examining for the first time whether aging stereotypes are powerful enough to implicitly permeate the clinical neuropsychological testing and thus inflate memory deficits in older adults judged "at risk" (based on either epidemiological criteria or memory complaints), resulting in false-positive detection of SCI and MCI. This provocative hypothesis will be tested while 1) using biomarkers of neurodegeneration to distinguish false-positives from true MCI, and 2) using biomarkers of stress to examine whether and how aging stereotypes can lead to acute physiological stress during neuropsychological testing. This innovative project has the potential to offer new recommendations to improve the diagnosis accuracy of prodromal state of AD, with positive consequences for older people's wellbeing.

03

Conditions studied

  • Mild Cognitive Impairment (MCI)
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be at least 50 years old
  • Patients must report memory complaints
  • Patients must show signs of MCI (amnestic single or multiple domain) on the following short cognitive tests

Exclusion criteria

Exclusion Criteria:

  • Probable Alzheimer's Disease according to NINCDS-ADRDA criteria (MA patients will be excluded from the study because false-positive errors only concern MCI status, not AD)
  • Psychiatric disorders (schizophrenia, bipolar disorder)
  • Cranial trauma
  • Developmental pathologies
  • Depression (score greater than or equal to 10 on GDS)
  • Psychotropic medication if modified in the last 3 months
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
130 participants (actual)

Study arms

  • Active comparator
    Standard instruction

    Diagnostic Test: Diagnosis of MCI versus No MCI (SCI or healthy patient)

  • Experimental
    Reduced threat instruction

    Diagnostic Test: Diagnosis of MCI versus No MCI (SCI or healthy patient)

Interventions

  • Diagnostic testDiagnosis of MCI versus No MCI (SCI or healthy patient)

    Neuropsychological tests

  • Diagnostic testDiagnosis of MCI versus No MCI (SCI or healthy patient)

    Neuroimaging biomarkers of neurodegeneration

06

What researchers measure

Primary outcomes

  1. Neuropsychological tests

    Neuropsychological battery used for the diagnosis of Mild Cognitive Impairment (MCI, amnestic single or multiple domain)

    Time frame: 48 months

Secondary outcomes

  1. Neuroimaging biomarkers of neurodegeneration

    Structural MRI (Hippocamp) and Florbetapir© PET (β-amyloid deposition)

    Time frame: 48 months

  2. Physiological stress

    cortisol, dehydroepiandrosterone (DHEA) and its sulfated stable form (DHEAS) from the HPA axis, and Immunoglobulin A (IgA).

    Time frame: 48 months

  3. Self-report questionnaires

    Vulnerability factors for stereotyping threat effects are assessed

    Time frame: 48 months

  4. Heart rate variability (thin elasticized heart rate transmitter belt),

    Physiological stress

    Time frame: 48 months

  5. Skin conductance (wristwatch)

    Physiological stress

    Time frame: 48 months

  6. Salivary biomarkers

    cortisol, dehydroepiandrosterone (DHEA) and its sulfated stable form (DHEAS) from the HPA axis, and Immunoglobulin A (IgA).

    Time frame: 48 months

07

Study locations

1 site
  • Assistance Publique Hôpitaux de Marseille
    Marseille, 13354, France
08

References and documents

Publications

  • Morand, A., Gauthier, K., Mazerolle, M., Pélerin, A., Rigalleau, F., de La Sayette, V., Eustache, F., Desgranges, B., Huguet, P., & Régner, I. (2020). L'effet de menace du stéréotype en situation d'évaluation neuropsychologique: Enjeux cliniques [The stereotype threat effect during neuropsychological assessment: Clinical issues]. Revue de Neuropsychologie, Neurosciences Cognitives et Cliniques, 12(4), 358-366.
  • Gauthier, K., Morand, A., Mazerolle, M., Rigalleau, F., Eustache, F., Desgranges, B., Huguet, P., & Régner, I. (2020). Effet de menace du stéréotype: Historique, mécanismes, et conséquences sur les performances cognitives des personnes âgées [The stereotype threat effect: Historical context, mechanisms, and impact on cognitive performance in older adults]. Revue de Neuropsychologie, Neurosciences Cognitives et Cliniques, 12(4), 351-357.
  • Gauthier K, Morand A, Dutheil F, Alescio-Lautier B, Boucraut J, Clarys D, Eustache F, Girard N, Guedj E, Mazerolle M, Paccalin M, de la Sayette V, Zarea A, Huguet P, Michel BF, Desgranges B; AGING consortium; Regner I. Ageing stereotypes and prodromal Alzheimer's disease (AGING): study protocol for an ongoing randomised clinical study. BMJ Open. 2019 Oct 7;9(10):e032265. doi: 10.1136/bmjopen-2019-032265. PubMed 31594904 ↗
  • Le Tirant L, Likhanov M, Mazerolle M, Morand A, Eustache F, Huguet P; AGING Consortium; Regner I. Self-Perceptions of Aging in Older Adults: A Network Analysis of Clinical and Non-Clinical Samples. Brain Sci. 2026 Feb 9;16(2):204. doi: 10.3390/brainsci16020204. PubMed 41750205 ↗
  • Regner I, Huguet P. Age-based stereotype threat effects: From the laboratory to the clinical setting. Cortex. 2025 Feb;183:261-273. doi: 10.1016/j.cortex.2024.12.006. Epub 2024 Dec 25. PubMed 39756332 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Aug 2023, 61 months.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 61 months is above that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Jul 2023 → Aug 2023 and completion Jul 2023 → Aug 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2017
First posted
May 3, 2017
StartActual
Jul 6, 2018
Primary completionActual
Aug 11, 2023was Jul 2023
CompletionActual
Aug 11, 2023was Jul 2023
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 21, 2026
Primary completion
Jul 1, 2023→Aug 11, 2023 (actual)
Oct 21, 2026
Study completion
Jul 1, 2023→Aug 11, 2023 (actual)
Oct 21, 2026
Enrollment
260 (estimated)→130 (actual)
Oct 21, 2026
Publications
Results publication added: Le Tirant L, Likhanov M, Mazerolle M, Morand A, Eustache F, Huguet P; AGING Consortium; Regner I. Self-Perceptions of Aging in Older Adults: A Network Analysis… PubMed 41750205 ↗; 1 more
Oct 26, 2026
Show all 2 updates
  1. Oct 26, 2026
    Publications Results publication added: Le Tirant L, Likhanov M, Mazerolle M, Morand A, Eustache F, Huguet P; AGING Consortium; Regner I. Self-Perceptions of Aging in Older Adults: A Network Analysis… PubMed 41750205 ↗; 1 more
  2. Oct 21, 2026
    Status unknown→Completed
    Primary completion Jul 1, 2023→Aug 11, 2023 (now actual)
    Study completion Jul 1, 2023→Aug 11, 2023 (now actual)
    Enrollment 260 (estimated)→130 (actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03138018
Responsible party
Sponsor
First posted
May 3, 2017
Start date
Jul 6, 2018
Primary completion
Aug 11, 2023
Completion
Aug 11, 2023
Last update
Oct 26, 2026

Study contacts

Urielle DESALBRES, Director
study director · ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion